FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation

AlloVir, Inc. announced that the US FDA has granted its lead multi-virus specific T cell therapy, posoleucel, RMAT designation for the treatment of AdV infection following allogeneic hematopoietic stem cell transplant. The designation is based on positive results from the Phase II CHARMS study.